Published Date: 02 Mar 2023
It has long been known that people who are overweight or obese are more prone to diseases such as high blood pressure and diabetes mellitus, which can lead to heart disease. But experts at the Mayo Clinic say obesity can...
Read Full NewsMiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.
Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.
1.
Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.
2.
Charting the Course: From Young Adult Leukemia Patient to Oncologist.
3.
Screening for prostate cancer: is it time to give up digital rectal examination?
4.
Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care
5.
Charles III, King of Kings, is Cancerous.
1.
The Growing Crisis of Aplastic Anemia: A Call for Action
2.
The Silent Killer: Uncovering the Causes and Treatments of Hemorrhagic Gastritis
3.
Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care
4.
Unlocking the Potential of Immune Checkpoint Inhibitors: A Pioneering Case Series on the Role of Immunotherapy in Microsatellite-Instability-High Colorectal Cancer
5.
Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation